Hospital
MT Graham Regional Medical Center INC
MT Graham Regional Medical Center INC was paid $27.72M by Medicaid between Jan 2018 and Dec 2024, across 231 billing codes. Its largest line is 99282, Emergency department visit for the evaluation and management, low to moderate severity — 18% of everything it billed.
33Billing provider infoMT GRAHAM REGIONAL MEDICAL CENTER INC
SAFFORD, AZ 85546
SAFFORD, AZ 85546
33aNPI1275588345assigned 05/24/2006
33bProvider typeRural Acute Care Hospital
28Total paid$27.72M
24GClaims609,976
24DCodes billed231
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Arizona
Rank by total paid#2 of 5
Median peer was paid$23.19M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 87,374 | $3.01M | |
| 2019 | 82,698 | $3.55M | |
| 2020 | 71,795 | $2.87M | |
| 2021 | 84,296 | $3.83M | |
| 2022 | 99,405 | $5.28M | |
| 2023 | 98,901 | $4.82M | |
| 2024incomplete | 85,507 | $4.36M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 18% | 37,761 | 34,045 | $4.90M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 34,460 | 31,746 | $4.78M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 16% | 5,792 | 5,307 | $4.41M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 15,415 | 13,489 | $3.00M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.0% | 5,317 | 4,524 | $1.39M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.0% | 4,525 | 4,123 | $1.38M |
| G0378 | Hospital observation service, per hour | 3.7% | 8,939 | 4,363 | $1.02M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.1% | 1,950 | 1,827 | $850K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.6% | 978 | 914 | $728K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 11,651 | 7,591 | $562K |
| 59025 | Fetal non-stress test | 1.8% | 2,361 | 1,564 | $504K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 975 | 919 | $458K |
219 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 19,889 | $407K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.0% | 408 | $286K |
| 97162 | <1% | 3,099 | $268K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,291 | $254K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,020 | $216K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,348 | $179K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 820 | $168K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,617 | $159K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,287 | $129K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,810 | $112K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,572 | $85K |
| 80053 | Comprehensive metabolic panel | <1% | 27,997 | $80K |
| 73562 | <1% | 1,915 | $67K | |
| 73130 | <1% | 1,741 | $66K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 624 | $62K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 390 | $62K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,031 | $62K |
| 73630 | <1% | 2,191 | $57K | |
| 93971 | <1% | 354 | $56K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,080 | $52K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 452 | $47K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 562 | $43K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,354 | $39K |
| 73030 | <1% | 1,235 | $37K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,646 | $37K |
| 73610 | <1% | 1,592 | $36K | |
| 72110 | <1% | 287 | $35K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 438 | $34K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 368 | $34K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 54 | $28K |
| 72100 | <1% | 275 | $27K | |
| 73110 | <1% | 1,174 | $26K | |
| 76801 | <1% | 97 | $26K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,748 | $25K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,516 | $24K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 216 | $23K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,205 | $23K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 98 | $23K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 752 | $22K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 156 | $21K |
| 76642 | <1% | 426 | $19K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 74 | $18K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 255 | $15K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 461 | $15K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 642 | $12K |
| 76830 | Ultrasound, transvaginal | <1% | 757 | $11K |
| 10060 | <1% | 134 | $11K | |
| 74018 | <1% | 248 | $11K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 108 | $10K |
| 95811 | <1% | 14 | $9K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,330 | $9K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,205 | $8K |
| 73502 | <1% | 337 | $7K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 53 | $7K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,102 | $7K |
| 73080 | <1% | 201 | $6K | |
| 86920 | <1% | 47 | $6K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 288 | $6K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 38 | $6K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,304 | $5K |
| 96376 | <1% | 4,223 | $5K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 30,748 | $5K |
| 72131 | <1% | 12 | $5K | |
| 97161 | <1% | 209 | $4K | |
| 70486 | <1% | 55 | $4K | |
| 87510 | <1% | 1,924 | $4K | |
| 96367 | <1% | 1,938 | $4K | |
| 86850 | <1% | 1,853 | $4K | |
| 76775 | <1% | 55 | $4K | |
| 84702 | <1% | 414 | $3K | |
| C1788 | Port, indwelling (implantable) | <1% | 43 | $3K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,121 | $3K |
| 80329 | <1% | 2,394 | $3K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 32 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,298 | $2K |
| 72141 | <1% | 13 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 18 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 17,838 | $2K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 29 | $2K |
| 94762 | <1% | 6,282 | $2K | |
| 87081 | <1% | 2,200 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 9,293 | $2K |
| 73090 | <1% | 88 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 704 | $2K |
| 72050 | <1% | 12 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,605 | $2K |
| 77080 | <1% | 14 | $2K | |
| 87400 | <1% | 3,379 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,144 | $1K |
| 87186 | <1% | 2,821 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 40,436 | $1K |
| 87480 | <1% | 1,925 | $1K | |
| 71250 | <1% | 12 | $1K | |
| 83880 | <1% | 1,811 | $1K | |
| 87088 | <1% | 5,221 | $904.19 | |
| 81025 | <1% | 5,424 | $868.38 | |
| 12011 | <1% | 16 | $866.23 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 25 | $862.92 |
| 76857 | <1% | 17 | $804.37 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 541 | $773.55 |
| 85027 | <1% | 2,231 | $773.36 | |
| 80061 | Lipid panel | <1% | 870 | $760.42 |
| 76981 | <1% | 58 | $741.66 | |
| 87420 | <1% | 123 | $714.66 | |
| 82803 | <1% | 820 | $701.20 | |
| 73590 | <1% | 45 | $494.12 | |
| 82948 | <1% | 4,782 | $448.78 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,245 | $448.08 |
| 87653 | <1% | 12 | $413.58 | |
| 81003 | <1% | 19,582 | $405.48 | |
| 74019 | <1% | 17 | $403.90 | |
| 97802 | <1% | 13 | $400.05 | |
| 97803 | <1% | 12 | $396.25 | |
| 83735 | <1% | 3,526 | $374.99 | |
| 85610 | <1% | 4,542 | $354.43 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,138 | $311.34 |
| 84703 | <1% | 2,337 | $306.06 | |
| 82607 | <1% | 188 | $278.92 | |
| 84484 | <1% | 7,316 | $275.81 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 93 | $273.26 |
| 90715 | <1% | 871 | $257.42 | |
| 85730 | <1% | 3,438 | $230.33 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 921 | $227.45 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,825 | $215.81 |
| 97116 | <1% | 104 | $208.85 | |
| 82728 | <1% | 82 | $187.49 | |
| 82962 | <1% | 1,455 | $180.73 | |
| 87040 | <1% | 2,998 | $179.60 | |
| 83690 | <1% | 5,087 | $175.38 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,886 | $175.01 |
| 84466 | <1% | 117 | $173.75 | |
| 90686 | <1% | 12 | $170.64 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,470 | $156.05 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,186 | $155.38 |
| 87070 | <1% | 553 | $148.14 | |
| 87077 | <1% | 2,854 | $130.33 | |
| 88304 | <1% | 178 | $103.43 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 217 | $84.53 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 886 | $83.20 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,770 | $81.38 |
| 86900 | <1% | 2,103 | $76.03 | |
| J1815 | Injection, insulin, per 5 units | <1% | 31 | $66.99 |
| 85379 | <1% | 88 | $61.50 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,400 | $60.36 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 43 | $58.67 |
| 86140 | <1% | 624 | $52.34 | |
| 83605 | <1% | 3,332 | $47.46 | |
| 82746 | <1% | 43 | $45.88 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 5,198 | $43.71 |
| 86592 | <1% | 126 | $38.02 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,237 | $33.69 |
| 82043 | <1% | 102 | $30.44 | |
| 87660 | <1% | 1,925 | $28.34 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,491 | $21.33 |
| 85652 | <1% | 579 | $20.74 | |
| 82550 | <1% | 868 | $19.36 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,432 | $17.84 |
| 80320 | <1% | 2,697 | $17.04 | |
| 82248 | <1% | 18 | $14.34 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 371 | $10.00 |
| 84100 | <1% | 44 | $8.56 | |
| 82272 | <1% | 13 | $7.33 | |
| 86901 | <1% | 2,103 | $5.48 | |
| 84156 | <1% | 42 | $4.04 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,333 | $3.24 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,546 | $0.99 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 315 | $0.03 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 3,019 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 2,235 | $0.00 |
| 94760 | 0% | 1,392 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,300 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 2,334 | $0.00 |
| 99156 | 0% | 315 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 351 | $0.00 |
| J3490 | Unclassified drugs | 0% | 1,243 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 675 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,963 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 49 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 1,712 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 90 | $0.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 772 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 627 | $0.00 |
| 88342 | 0% | 278 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 23 | $0.00 |
| 12001 | 0% | 164 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 60 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 201 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 586 | $0.00 |
| 91301 | 0% | 12 | $0.00 | |
| 83615 | 0% | 65 | $0.00 | |
| 87340 | 0% | 67 | $0.00 | |
| 88341 | 0% | 30 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 26 | $0.00 |
| 97014 | 0% | 72 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 18 | $0.00 |
| 86762 | 0% | 13 | $0.00 | |
| G0379 | Direct admission of patient for hospital observation care | 0% | 16 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 13 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 400 | $0.00 |
| 84145 | 0% | 26 | $0.00 | |
| S0028 | Injection, famotidine, 20 mg | 0% | 341 | $0.00 |
| 0502F | 0% | 1,115 | $0.00 | |
| 84439 | 0% | 532 | $0.00 | |
| 83540 | 0% | 132 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 339 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 267 | $0.00 |
| 86787 | 0% | 25 | $0.00 | |
| 84460 | 0% | 17 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 158 | $0.00 |
| 82570 | 0% | 259 | $0.00 | |
| 82010 | 0% | 15 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 41 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 387 | $0.00 |
| 85007 | 0% | 14 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 115 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
| 94664 | 0% | 16 | $0.00 | |
| 82140 | 0% | 16 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKNOX, ROLAND (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Northern Cochise Community Hospital INC | Willcox, AZ | $8.39M |
| Sulphur Springs Medical Center | Willcox, AZ | $1.29M |
| Northern Cochise Community Hospital | Willcox, AZ | $79K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.